Benzinga | Sep 20, 2021 04:02PM EDT

Boston Scientific Posts Colorectal Cancer Survival Data For Tumor-Targeting Microbeads

* Boston Scientific Corporation (NYSE:BSX) announced that the EPOCH clinical trial of the TheraSphere Y-90 Glass Microspheres (TheraSphere treatment) met both primary endpoints.

* The results of a long-term study showed that adding TheraSpheres to a standard chemotherapy regimen could extend survival for patients with colorectal cancer that has spread to the liver.

* Each of the beads contains a small but mighty dose of Y-90, a radioactive isotope of yttrium with a half-life of fewer than three days.

* The beads are planted directly in a tumor by a catheter, helping minimize the dose and damage to nearby healthy tissues.

* In the study, TheraSpheres were used in tandem with chemotherapy as a second-line treatment for liver-dominant colorectal cancer patients who saw their disease worsen either during or after their chemo.

* TheraSpheres were found to be 31% less likely than the control group to show disease progression or death due to any cause and just over 40% less likely to experience hepatic disease progression or death.

* Earlier this year, TheraSpheres was approved by the FDA for hepatocellular carcinoma, the most common type of primary liver cancer.

* Related content: Benzinga's Full FDA Calendar.

* Price Action: BSX stock closed lower by 1.63% at $43.65 on Monday.